Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta
Within weeks of its acquisition of Kite, Gilead is working to launch its first immuno-oncology drug, with a goal of training 70-90 US cancer centers. Q3 saw continued increase in HIV sales, decrease in HCV revenues.
You may also be interested in...
Slow and steady approach to launch should position Yescarta well in the long run, Gilead maintains – the CAR-T therapy brought in $7m in its first month. But Gilead is still suffering from the decline in hepatitis C.
Hemophilia and immuno-oncology will be in the spotlight as earnings season continues into February. Will Bristol be a buyer or an acquisition target? How will Sanofi fare with its new acquisitions? And how will Teva and GSK fare as they face generics for top brands?
Much like it did for the first biosimilars, US FDA approved Yescarta without an advisory committee, as Novartis' first-in-class CAR-T cell therapy already set the stage for an agency review.